Apertus Pharmaceuticals

Apertus Pharmaceuticals is a private, revenue-generating CDMO founded in 2016 and headquartered in San Diego, with an FDA-inspected manufacturing facility in Saint Louis. The company operates as a service provider in the biopharma sector, offering end-to-end support in API procurement, analytical and formulation development, and manufacturing of various dosage forms, including suppositories, capsules, tablets, and topicals. Its business model is focused on serving other pharmaceutical companies, particularly with small to medium batch production needs. While the initial data suggested an oncology focus, the website content reveals a broader service-based CDMO model without a proprietary therapeutic pipeline.

Integrated CDMO service platform offering API services, analytical & formulation development, and cGMP manufacturing for various dosage forms including sterile injectables, potent compounds, nasal sprays, and solid/semi-solid dosages.

Apertus competes in the fragmented pharmaceutical CDMO market. It faces competition from large, full-service global CDMOs (e.g., Lonza, Catalent), mid-sized specialists, and smaller boutique labs. Its differentiation is based on small-to-medium batch capabilities, expertise in specific complex dosage forms, and a US-based facility, rather than scale or lowest cost.